Resources
43 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/3/2021 (updated 4/10/2024)
During this session, TELs reviewed the Cohort specific sustainability template and answer questions from grantees ahead of the HRSA due dates in the fall.
Posted 5/17/2021 (updated 4/10/2024)
This webinar will present the OUD Cascade of Care, explain how to create one for your program and use it to evaluate and sustain your MOUD continuum of care.
Learning Objectives:
Understand the cascade of care for opioid use disorder (OUD)
Define metrics for your OUD cascade of care
Use the cascade of care to take action that improves sustainability
Target Audience: Implementation I, Implementation II, MAT Expansion, but all cohorts are welcome
Posted 5/10/2021 (updated 4/10/2024)
Participants will be provided an overview on how to appropriately document, code and bill for encounters throughout the SUD/OUD continuum of care following CMS billing rules for FQHCs/RHC. An overview of the opportunities and challenges associated with MAT reimbursement mechanisms including coding and billing for Medicare, managed care, Medicaid, and other third-party payors will also be presented as will a brief description of revenue options for reporting Transitional Care Management, Virtual Communication Services, Telehealth, and other care management services such as Behavioral Health Integration and the Psychiatric Collaborative Care Model.
Posted 5/5/2021 (updated 4/10/2024)
We discussed the importance of engaging community influencers in your efforts to improve prevention, treatment, and recovery systems and services. We talked about how to identify and engage these key community stakeholders and why this strategic activity is vital to your consortium’s sustainability.
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 4/1/2021 (updated 4/5/2024)
This webinar will introduce attendees to the infrastructure, implementation, impact and adaptation of Regrounding. Our Response, a statewide effort to address stigma through collective impact underway in Maryland and being adapted in West Virginia. Structured around 5 curriculum areas, each addressing a persistent myth instrumental in upholding stigma related SUD/OUD, the content is delivered within the state at no cost by one of the 25 master presenters trained from across regions and sectors—a process being captured by the Association of State and Territorial Health Officers, who are producing a toolkit that is forthcoming.
Posted 4/1/2021 (updated 4/5/2024)
This webinar will provide an overview of COVID-19 impacts and vaccination attitudes among SUD populations in Vermont including people who use drugs, patients receiving MAT, and people in recovery. It will outline the methods undertaken to conduct a community-based survey. It will discuss the barriers and opportunities that arose from analysis of the survey and a subsequent consortium workshop.
Posted 3/2/2021 (updated 4/4/2024)
This session will walk through the strategic plan template provided by JBS International in the Grantee Onboarding Packet for HRSA RCORP-Planning Grantees. During this workshop style webinar, facilitators will walk grantees through the template section by section, discussing the required elements and providing examples of each section. Grantees will learn how to use their data to determine problem statements, goals, objectives, and outcomes for their strategic plan as well as how to include metrics to successfully track their progress.